Geneoscopy, Inc. raised $105 million in a Series C funding round led by Bio-Rad Laboratories to advance their at-home colorectal cancer screening test, ColoSense.
PRIVATEJan 08, 2025
Amount Raised
$105 Million
Round Type
Series C
St. LouisBiotechnologyHealthcareHealth CareTherapeuticsHealth Diagnostics
Investors
Bio-Rad LaboratoriesNt InvestmentsLightchain CapitalMercy HealthGranger ManagementPetrichorLabcorpMorningside VenturesTri Locum Partners
Description
Geneoscopy, Inc. has successfully closed a Series C funding round, raising $105 million to further the development of its gastrointestinal diagnostic tests. The funding will facilitate the launch of the ColoSense test and ongoing investment in innovative diagnostic solutions for inflammatory bowel disease.
Company Information
Company
Geneoscopy
Location
2220 WELSCH INDUSTRIAL CT.
St. Louis, Missouri, United States
About
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.
Fundz sees it the moment Geneoscopy raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
St. LouisBiotechnologyHealthcareHealth CareTherapeuticsHealth Diagnostics